カテゴリ： GlobalData, ドイツ, 企業調査

Evotec AG (EVT)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Evotec AG (EVT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012267
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：169
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and Munich, Germany; South San Francisco, Branford and Princeton, the US; and Toulouse, France. Evotec is headquartered in Hamburg, Germany.

Evotec AG (EVT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 8
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Evotec AG, Medical Devices Deals, 2011 to YTD 2017 14
Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Evotec AG, Pharmaceuticals & Healthcare, Deal Details 21
Venture Financing 21
Forge Therapeutics Raises USD15 million in Series A Financing 21
Eternygen Raises USD8.4 Million in Series A Financing 22
Carrick Therapeutics Raises USD95 Million in Venture Financing 23
Topas Therapeutics Raises USD15.8 Million in Series A Financing 24
Partnerships 26
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 26
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 27
Evotec and Tesaro Enter into Agreement 29
Forge Therapeutics and Evotec Enter into Partnership 30
Evotec and Abivax Enter into Partnership 31
Evotec Enters into Partnership with Fraunhofer 32
Evotec Enters into Agreement with Censo Biotech 33
Bioversys and Aptuit Enter into Partnership 34
Dementia Discovery Fund and Aptuit Enter into Partnership 35
Aptuit Enters into Agreement with Massachusetts General Hospital 36
Evotec Enters into Agreement with Asahi Kasei Pharma 37
Evotec Forms Joint Venture with MaRS Innovation 38
Chronos Therapeutics Partners with Aptuit 39
Aptuit Enters into Agreement with Chiesi Farmaceutici 40
Evotec Expands Agreement with Storm Therapeutics 41
Evotec Enters into Research Agreement with Celgene 42
Evotec Enters into Agreement with Forge Therapeutics 43
Evotec Partners with Merck 44
Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 45
Evotec Enters into Agreement with C4X Discovery 46
Evotec Enters into Research Agreement with Inserm Transfert 47
Bayer Enters into Partnership with Evotec 48
Evotec Enters into Agreement with Antibiotic Research UK 49
Aptuit Enters into Agreement with Dimension Therapeutics 50
Trianni Enters into Agreement with Evotec 51
Evotec Forms Partnership with Ex Scientia 52
Evotec Partners with Pierre Fabre Labs 53
Icagen Partners with Aptuit 54
Evotec Partners with UCB 55
Evotec Extends its Agreement with Spero Therapeutics 56
Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 57
Evotec Enters into Research Agreement with Sanofi 58
Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 59
Evotec Enters into Agreement with Facio Therapies 60
Second Genome Enters into Agreement with Evotec 61
SAMDI Tech Enters into Agreement with Exquiron 62
Evotec Enters into Research Agreement with C4X Discovery 63
Evotec Enters into Research Agreement with Ohio State University 64
Evotec Extends Research Agreement with C4X Discovery 65
Evotec to Enter into Co-Development Agreement with Sanofi 66
Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 68
Evotec Enters into Co-Development Agreement with Eternygen 69
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 70
Evotec Enters into Agreement with Padlock Therapeutics 71
Evotec Extends Agreement with Padlock Therapeutics 72
Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 73
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 74
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 75
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 76
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 77
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 78
Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 79
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 80
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 81
Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 82
Apredica Enters Into Research Agreement With Pfizer 83
Evotec Extends Co-Development Agreement With CHDI Foundation For Huntington’s Disease Drugs 84
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 85
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 86
Evotec Extends Co-Development Agreement With Active Biotech 87
Evotec Enters Into Co-Development Agreement With IR Pharma 88
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 89
Sygnature Discovery Extends Partnership Agreement With Cyprotex Discovery 91
Evotec Enters Into Co-Development Agreement With APEIRON Biologics 92
Evotec Enters Into Co-Development Agreement With UCB 93
Evotec Enters Into Co-Development Agreement With Roche 94
Evotec Enters Into Drug Discovery Collaboration With UCB 95
Ono Pharma Extends Research Agreement With Evotec 96
Evotec Enters Into An Agreement With Active Biotech 97
Evotec Enters Into Research Collaboration With Harvard University And Howard Hughes Medical Institute 98
Evotec Enters Into Collaboration With Takeda Cambridge 99
Licensing Agreements 100
Evotec Enters into Licensing Agreement with Ncardia 100
Evotec Enters Into Licensing Agreement With Debiopharm 101
Evotec Enters into Licensing Agreement with Broad Institute 102
Pfizer Enters into Licensing Agreement with Evotec 103
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 104
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 105
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 106
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 108
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 109
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 110
Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 112
Equity Offering 113
Facio Therapies Raises USD5.4 Million in Equity Financing 113
Evotec to Raise USD96.4 Million in Private Placement of Shares 114
Evotec Receives Investment from Ellersbrook 115
Evotec Spin Out from Topas Therapeutics 116
Evotec Completes Private Placement Of Shares For US$40 Million 117
Asset Transactions 119
Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For US$410 Million 119
Acquisition 120
Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 120
Evotec Acquires Aptuit for USD300 Million 121
Evotec Acquires Cyprotex for USD68 Million 123
Aptuit Acquires Kuecept 125
Aptuit Acquires Exquiron Biotech 126
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 127
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 128
Evotec Acquires Bionamics, Asset Management Company 129
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 130
Evotec Acquires CCS Cell Culture Service, Contract Research Organization 131
Evotec Acquires DeveloGen For USD18 Million 132
Evotec Completes Acquisition Of Remaining 30% Stake In Evotec (India) For US$2.3 Million 134
Evotec Acquires Compound Focus 135
Evotec Completes Acquisition Of Kinaxo Biotechnologies 136
Evotec AG – Key Competitors 138
Evotec AG – Key Employees 139
Evotec AG – Locations And Subsidiaries 140
Head Office 140
Other Locations & Subsidiaries 140
Joint Venture 141
Recent Developments 142
Financial Announcements 142
Nov 08, 2017: Evotec announces first nine-month 2017 results and corporate update 142
Aug 10, 2017: Evotec Announces First Half Year 2017 Results 146
May 10, 2017: Evotec Announces First Quarter 2017 Results and Corporate Update 149
Mar 28, 2017: Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery 152
Nov 10, 2016: Evotec Reports Results of First Nine Months of 2016 156
Aug 10, 2016: Evotec reports results of first half of 2016 159
May 10, 2016: Evotec Reports Results of First Quarter 2016 161
Mar 22, 2016: Evotec FY 2015: Excellent Execution Meets First-in-Class Innovation 164
Government and Public Interest 166
Feb 21, 2017: Evotec: ‘LAB282′ awarded first projects 166
Feb 02, 2016: Evotec awarded grant from The Michael J. Fox Foundation for Parkinson’s Research 167
Product News 168
Jan 12, 2016: Evotec Achieves Important Milestone in TargetAD Collaboration with Janssen in Alzheimer’s Disease 168
Appendix 169
Methodology 169
About GlobalData 169
Contact Us 169
Disclaimer 169

List of Tables
Evotec AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Evotec AG, Deals By Therapy Area, 2011 to YTD 2017 12
Evotec AG, Medical Devices Deals, 2011 to YTD 2017 14
Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Forge Therapeutics Raises USD15 million in Series A Financing 21
Eternygen Raises USD8.4 Million in Series A Financing 22
Carrick Therapeutics Raises USD95 Million in Venture Financing 23
Topas Therapeutics Raises USD15.8 Million in Series A Financing 24
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 26
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 27
Evotec and Tesaro Enter into Agreement 29
Forge Therapeutics and Evotec Enter into Partnership 30
Evotec and Abivax Enter into Partnership 31
Evotec Enters into Partnership with Fraunhofer 32
Evotec Enters into Agreement with Censo Biotech 33
Bioversys and Aptuit Enter into Partnership 34
Dementia Discovery Fund and Aptuit Enter into Partnership 35
Aptuit Enters into Agreement with Massachusetts General Hospital 36
Evotec Enters into Agreement with Asahi Kasei Pharma 37
Evotec Forms Joint Venture with MaRS Innovation 38
Chronos Therapeutics Partners with Aptuit 39
Aptuit Enters into Agreement with Chiesi Farmaceutici 40
Evotec Expands Agreement with Storm Therapeutics 41
Evotec Enters into Research Agreement with Celgene 42
Evotec Enters into Agreement with Forge Therapeutics 43
Evotec Partners with Merck 44
Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 45
Evotec Enters into Agreement with C4X Discovery 46
Evotec Enters into Research Agreement with Inserm Transfert 47
Bayer Enters into Partnership with Evotec 48
Evotec Enters into Agreement with Antibiotic Research UK 49
Aptuit Enters into Agreement with Dimension Therapeutics 50
Trianni Enters into Agreement with Evotec 51
Evotec Forms Partnership with Ex Scientia 52
Evotec Partners with Pierre Fabre Labs 53
Icagen Partners with Aptuit 54
Evotec Partners with UCB 55
Evotec Extends its Agreement with Spero Therapeutics 56
Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 57
Evotec Enters into Research Agreement with Sanofi 58
Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 59
Evotec Enters into Agreement with Facio Therapies 60
Second Genome Enters into Agreement with Evotec 61
SAMDI Tech Enters into Agreement with Exquiron 62
Evotec Enters into Research Agreement with C4X Discovery 63
Evotec Enters into Research Agreement with Ohio State University 64
Evotec Extends Research Agreement with C4X Discovery 65
Evotec to Enter into Co-Development Agreement with Sanofi 66
Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 68
Evotec Enters into Co-Development Agreement with Eternygen 69
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 70
Evotec Enters into Agreement with Padlock Therapeutics 71
Evotec Extends Agreement with Padlock Therapeutics 72
Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 73
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 74
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 75
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 76
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 77
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 78
Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 79
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 80
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 81
Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 82
Apredica Enters Into Research Agreement With Pfizer 83
Evotec Extends Co-Development Agreement With CHDI Foundation For Huntington's Disease Drugs 84
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 85
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 86
Evotec Extends Co-Development Agreement With Active Biotech 87
Evotec Enters Into Co-Development Agreement With IR Pharma 88
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 89
Sygnature Discovery Extends Partnership Agreement With Cyprotex Discovery 91
Evotec Enters Into Co-Development Agreement With APEIRON Biologics 92
Evotec Enters Into Co-Development Agreement With UCB 93
Evotec Enters Into Co-Development Agreement With Roche 94
Evotec Enters Into Drug Discovery Collaboration With UCB 95
Ono Pharma Extends Research Agreement With Evotec 96
Evotec Enters Into An Agreement With Active Biotech 97
Evotec Enters Into Research Collaboration With Harvard University And Howard Hughes Medical Institute 98
Evotec Enters Into Collaboration With Takeda Cambridge 99
Evotec Enters into Licensing Agreement with Ncardia 100
Evotec Enters Into Licensing Agreement With Debiopharm 101
Evotec Enters into Licensing Agreement with Broad Institute 102
Pfizer Enters into Licensing Agreement with Evotec 103
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 104
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 105
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 106
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 108
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 109
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 110
Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 112
Facio Therapies Raises USD5.4 Million in Equity Financing 113
Evotec to Raise USD96.4 Million in Private Placement of Shares 114
Evotec Receives Investment from Ellersbrook 115
Evotec Spin Out from Topas Therapeutics 116
Evotec Completes Private Placement Of Shares For US$40 Million 117
Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For US$410 Million 119
Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 120
Evotec Acquires Aptuit for USD300 Million 121
Evotec Acquires Cyprotex for USD68 Million 123
Aptuit Acquires Kuecept 125
Aptuit Acquires Exquiron Biotech 126
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 127
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 128
Evotec Acquires Bionamics, Asset Management Company 129
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 130
Evotec Acquires CCS Cell Culture Service, Contract Research Organization 131
Evotec Acquires DeveloGen For USD18 Million 132
Evotec Completes Acquisition Of Remaining 30% Stake In Evotec (India) For US$2.3 Million 134
Evotec Acquires Compound Focus 135
Evotec Completes Acquisition Of Kinaxo Biotechnologies 136
Evotec AG, Key Competitors 138
Evotec AG, Key Employees 139
Evotec AG, Subsidiaries 140
Evotec AG, Joint Venture 141

★海外企業調査レポート[Evotec AG (EVT)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Harbin Gloria Pharmaceuticals Co Ltd (002437)-製薬・医療分野：企業M&A・提携分析
    Summary Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products comprise pharmaceutical drugs for treating nutrition disorders, cardiovascular diseases, cancer and musculoskeletal disorders. Its pipeline pro …
  • FluGen Inc-製薬・医療分野：企業M&A・提携分析
    Summary FluGen Inc (FluGen) is a healthcare services provider that offers vaccine and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu that contains mutations in the M2 gene of the virus. …
  • Quantum Genomics SA (ALQGC)：企業の財務・戦略的SWOT分析
    Summary Quantum Genomics SA (Quantum Genomics) is a bio pharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition ( …
  • Goldman Sachs Private Wealth Management：企業の戦略・SWOT・財務分析
    Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Jersey Oil and Gas Plc (JOG)：企業の財務・戦略的SWOT分析
    Summary Jersey Oil and Gas Plc (Jersey Oil), formerly Trap Oil Group Plc is an upstream oil and gas exploration and production company. The company acquires, explores, develops and produces natural gas properties in the UK continental shelf. Its oil and gas properties include Homer Block, Cortina Bl …
  • Albireo Pharma Inc (ALBO)：企業の財務・戦略的SWOT分析
    Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kuwait Petroleum Corporation：企業の戦略的SWOT分析
    Kuwait Petroleum Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • AvStar Aviation Services Inc：企業の戦略的SWOT分析
    AvStar Aviation Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • New York Life Insurance Company：企業のM&A・事業提携・投資動向
    New York Life Insurance Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New York Life Insurance Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Holland Colours NV (HOLCO)：企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • CESC Limited (CESC)：企業の財務・戦略的SWOT分析
    CESC Limited (CESC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The Chemours Company LLC：企業の戦略・SWOT・財務情報
    The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report Summary The Chemours Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • United States Endoscopy Group Inc：企業の戦略的SWOT分析
    United States Endoscopy Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Deutsche Lufthansa AG：企業のM&A・事業提携・投資動向
    Deutsche Lufthansa AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Lufthansa AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Ironwood Pharmaceuticals Inc (IRWD)：企業の財務・戦略的SWOT分析
    Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Merial Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Merial Ltd (Merial), a subsidiary of Boehringer Ingelheim GmbH, is an animal healthcare center that produces and markets pharmaceutical products and vaccines. The center offers products for dogs, cats, beef, dairy, equine, and swine to improve their health and performance. It develops specif …
  • Emisphere Technologies Inc (EMIS)：企業の戦略的SWOT分析
    Emisphere Technologies Inc (EMIS) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Bsquare Corporation (BSQR)：企業の財務・戦略的SWOT分析
    Bsquare Corporation (BSQR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NV Nederlandse Spoorwegen：企業の戦略・SWOT・財務情報
    NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report Summary NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Blackbird Energy Inc (BBI)：企業の財務・戦略的SWOT分析
    Summary Blackbird Energy Inc (Blackbird Energy), formerly Blackbird Investments Inc, is an independent oil and gas exploration and development company that acquires, explores, produces and develops oil and gas properties in Western Canada. The company holds interests in Elmworth Project which concen …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆